Hims & Hers Cuts Full-Year Outlook After Surprise Q3 Loss; Q4 Guidance Misses Consensus
HIMS sits 63% above its 52-week low of $13.74 on elevated volume (4.4× avg).
Summary
Hims & Hers narrowed full-year revenue guidance to $3.13B-$3.15B from $3.1B-$3.3B and cut its adjusted EBITDA outlook after a surprise Q3 loss of $33M, or 14 cents a share, versus the 6-cent profit analysts expected. The fourth-quarter guide of $875M-$895M lands well below the $953.8M consensus, so the miss extends into the current period rather than being a one-quarter cost blip. Cost of revenue more than doubled and total operating expenses rose 34%, dragging gross margin to 57% from 74% a year earlier even as revenue grew 49% to $890.4M. The company also disclosed the price of its Huberman arrangement: $3.5M in cash over two years for advisory services, up to $1M a year for short-form ads, and up to $5M annually for Scicomm Media podcast advertising over up to three years. The margin compression plus a soft Q4 guide is the part that matters — growth is intact but the cost of getting it is eating the profit line.
At the time of this announcement, HIMS was trading at $22.33 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $13.74 to $42.70. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.